Objective: The purpose of this study was to determine the ability of the ratio of free to total prostate-specific antigen and prostate-specific antigen density to predict the presence of clinically significant prostate cancer on template biopsies. The value of these tests may be underestimated as they were previously validated against sextant transrectal biopsy of the prostate, which has been proved to miss a large proportion of significant prostate cancers. The ability of these tests to specifically detect clinically significant cancers has not previously been studied. Patients and methods: A retrospective analysis was performed of patients undergoing transperineal template biopsy who also had free to total prostate-specific antigen and prostate-specific antigen density. Receiver-operating characteristic analysis was performed to determine the comparative utility of each test in the detection of all cancers as well as clinically significant cancers, by means of the area under the curve. Results: Data from 293 patients were analysed. Prostate cancer was detected in 72% of patients, of which 62% of this group had clinically significant disease. Receiver-operating characteristic analysis demonstrated the superiority of prostate-specific antigen density and free to total prostate-specific antigen over standard prostate-specific antigen in the overall detection of cancer (area under the curve 0.662 and 0.674 vs 0.534, p=0.003 and 0.02 respectively). Both tests were even more effective in the detection of clinically significant cancers (area under the curve 0.755 and 0.715 vs 0.572, p<0.0001 and 0.009 respectively). Conclusion: The free to total prostate-specific antigen and prostate-specific antigen density both appear to perform well at detecting clinically significant prostate cancer in our population of men undergoing template biopsy. The potential role of these inexpensive tests should not be overlooked as they may be of value when deciding which patients require biopsy following an initial magnetic resonance imaging scan and also for those on surveillance protocols.
Introduction
The results from the Prostate MRI Imaging Study (PROMIS) trial 1 have highlighted both the possible benefits of multiparametric magnetic resonance imaging (MRI) as an initial triage tool when a suspicion of prostate cancer exists, as well as confirming the poor attributes of transrectal ultrasound scan (TRUS)-guided biopsy as a diagnostic test for the investigation of suspected prostate cancer. Trans-rectal prostatic biopsies (TRUS) miss a significant proportion of cancers, particularly tumours in the anterior and apical regions of the gland. 2 In addition, there is significant understaging of cancer detected by transrectal biopsy, and several studies have shown that between 37-68% of men with prior negative TRUS biopsies have cancer subsequently detected by transperineal template mapping (TPM) biopsies. 2, 3 TRUS biopsy should therefore be considered a suboptimal reference in the evaluation of biomarkers given its ability to miss significant disease, and it is a long time since the calculation of the free to total prostate-specific antigen (F:T PSA) ratio was first advocated by Catalona et al., 4 as an adjunct to prostate-specific antigen (PSA) in order to reduce the likelihood of unnecessary TRUSguided prostate biopsies. With a cut-off value of 23%, it was suggested that a significant number of TRUS biopsies could be safely avoided in men with a total PSA ranging from 2.5-10 ng/ml and a benign-feeling prostate on rectal examination. The determination of PSA density (PSA/ prostate volume) has also been suggested as a method of risk-stratification and has been demonstrated to have comparable predictive values to F:T PSA. 5 As the application of the F:T PSA ratio and PSAD were previously validated against TRUS biopsy as the reference standard, we aimed to examine these inexpensive and widely available tests in a population of men undergoing a more detailed biopsy technique with a greater diagnostic accuracy. These inexpensive tests, if applied to the new diagnostic pathway, may enable us to reduce the number of men requiring biopsy; either following an initial Multiparametric Magnetic Resonance Imaging (MP-MRI) demonstrating an equivocal lesion or as part of an active surveillance protocol. The costs of incorporating MP-MRI into routine clinical practice will be huge and even a modest reduction in the proportion of men undergoing biopsy cannot be overlooked.
Methods
Data was analysed for patients undergoing TPM at our institution between January 2008-May 2013. The study population consisted of men with a PSA≤15 ng/ml who had undergone TPM for diagnosis, risk stratification, active surveillance or mapping with a view to focal ablative therapy. Only patients with incomplete datasets were excluded from analysis.
PSA and F:T PSA levels were measured at the time of preassessment within a month of when the template biopsies were scheduled to take place. Trans-rectal ultrasound volume estimations were measured at the time of biopsy, and the PSA density was calculated.
All men underwent TPM biopsies under general anaesthetic at 5 mm intervals as described by Bott et al. 2 The reported histopathological findings were recorded on our database.
Statistical analysis of the collected data was carried out using MedCalc software, including receiver operating characteristic (ROC) analysis to determine the comparative sensitivity and specificity for PSA, F:T PSA and PSAD as well as a range of suitable cut-off points to provide the best balance of the two.
Analysis for overall cancer detection as well as the detection of only clinically significant cancers was carried out. Clinical significance was determined using criteria suggested by Ahmed et al. 3 in the context of transperineal template biopsies, specifically Gleason grade and maximum cancer core length (MCCL) (see Figure 1 ). The presence of any Gleason grade 4 tumour was considered clinically significant, as was MCCL of >3 mm.
Results
A total of 366 TPMs were performed between January 2008-December 2013 for diagnosis, risk stratification, active surveillance and mapping for focal therapy. An upper PSA limit of 15 was chosen as greater than 50% of patients with a PSA at this level would be likely to have a positive biopsy based on risk calculation from the European Randomised Study of Screening for Prostate Cancer (ERSPC). Data from 293 patients remained for analysis.
The median age of the patients investigated was 66 years (35-79). The median prostate volume (measured at time of biopsy) was 47 cc (11-158), while median PSA was 7.9 (0.56-14.8) ng/ml and median free to total (F:T) ratio 12.7% (2.3-40.4). Median PSAD was 0.15 (0.01-1.16) ng/ml/ml. The number of cores sampled during TPMs ranged from 8-132 with a median of 47.
A total of 211 patients had prostate cancer diagnosed on TPM and 82 had benign histology, giving a prostate cancer (CaP) detection rate of 72%. Of these, 124 (62%) had clinically significant disease and 77 (38%) were deemed to have clinically insignificant disease; complete histological data was unavailable for 10 patients.
ROC analysis demonstrated that PSAD and F:T PSA were significantly better than PSA alone in the overall detection of prostate cancer, as illustrated in Figure 2 . Table 1 summarises the findings for performance of each test for overall cancer detection.
When ROC analysis was performed for the detection of clinically significant prostate cancers, both PSAD and F:T PSA showed further improvement over standard PSA, illustrated in Figure 3 . Table 2 summarises the findings for performance of each test for the detection of clinically significant cancers.
The values for sensitivity and specificity for the detection of clinically significant prostate cancers at a selection of cut-off values for PSAD and F/T ratio are listed in Tables 3 and 4 . It is notable that the risk of clinically significant cancer rises sharply from the PSAD value of 0.1 upwards. A PSA F:T cut-off value of 17.9% will have sensitivity of over 90% in detecting clinically significant cancers with a negative predictive value over 80%.
Discussion
In summary, our results show that both PSAD and F:T ratio were significantly better at predicting the likelihood of clinically significant cancer on biopsy when compared to PSA alone in the population studied, and were also useful in the prediction of clinically significant disease. These results would appear to support the potential clinical application of PSAD and the F:T ratio in the decision making process prior to undertaking biopsy.
In this series there was a steady drop in sensitivity of the F:T ratio below 12%. We would suggest an upper cutoff value of 18% rather than the 25% previously advocated in the era of TRUS biopsy. PSAD in this series showed a sharp rise in the detection of clinically significant disease from a value of 0.1 to 0.2. While we advocate a cut-off value for diagnosis of 0.23, the clinician should consider the implications of a PSAD between 0.1-0.2 as suspicious.
Among the limitations of this study is the retrospective collection of data, which led to a proportion of the intended study population being excluded from analysis due to incomplete data being available. Also, whilst it was departmental policy to test the F:T PSA ratio at the time of pre-assessment for biopsy, some may have had this performed earlier and this may have influenced the decision to proceed to this test. A further limitation is the use of biopsy results as the sole determinant of clinical significance, when in clinical practice other factors such as age and co-morbidities may have considerable clinical relevance. We believe that a strength of this study is the use of saturation template biopsy as the diagnostic standard, which is likely to provide a more accurate reflection of the true pathological diagnosis compared to standard trans-rectal biopsies.
Epstein et al. 6 investigated the F:T ratio in radical prostatectomy specimens, but only in those who they deemed as having had clinically insignificant disease. Their suggested cut-off value of 15% is lower than that suggested in our series and also to the previously suggested value of 25% based on TRUS biopsy. Excellent correlation of around 95% between saturation transperineal template biopsy (TTB) and radical prostatectomy findings has previously been demonstrated, 7 so it is possible that the differing cut-off values reflect a more heterogeneous patient group studied in this series.
Considerable research is ongoing to discover novel biomarkers that may aid in the early diagnosis of prostate cancer. To date, however, few of these have proven viable or are available for routine clinical use. An exception is the Prostate Cancer Antigen 3 (PCA3) test, which may lead to improved early detection and help to avoid unnecessary biopsy. 8 PCA3 has been compared against F:T PSA and found to be similar in sensitivity and specificity with a cutoff value of 20 for PCA3 and 25% for F:T PSA. Further evaluation of these two tests, using them as criteria in risk stratification also showed a similar performance. 9 However, the F:T PSA test is more widely available and in many centres costs significantly less than PCA3. At our centre the cost of a F:T ratio is only £19 (standard PSA costs £1) compared to over £400 for a PCA3 test performed privately. PSAD is essentially cost-neutral, as TRUS estimation of prostate volume is routinely undertaken at consultation.
Algorithms combining PSA, F:T PSA and other novel biomarkers such as the Prostate Health Index (PHI) and the kallikrein panel (4K) show promise for more accurate early diagnosis of clinically significant prostate cancer. The PHI incorporates measurement of [-2]proPSA, an isoform of free PSA, together with total PSA and the F:T PSA. Initial studies have shown that it can outperform the individual components of the test in the detection of clinically significant disease. 10, 11 The 4K test incorporates testing of kallikrein-related peptidase 2 in addition to free, intact and total PSA and has been shown to improve detection of prostate cancer over standard PSA testing. 12 It may also have value when used in conjunction with PCA3 to further increase predictive ability. 13 Few other biomarkers have validated clinical usefulness and are in routine clinical use at the present time. It is interesting to note that the majority of these algorithms were validated against six or 12-core transrectal biopsies as a diagnostic standard.
Multi-parametric MRI of the prostate is likely to play a greater role in the diagnostic pathway for prostate cancer in the coming years. A move towards image directed targeted biopsy is likely and appears to be supported by the early data coming through. MRI-targeted biopsy has a high detection rate for clinically significant disease and requires fewer biopsies. It also reduces the number of insignificant cancers detected. 14 It is worth noting that the area under the curve (AUC) for F:T and PSAD were improved for detecting clinically significant disease compared with all cancers.
If we were able to use these F:T and PSAD measurements to help with decision-making around when to biopsy equivocal lesions on MRI, the proportion of men undergoing biopsy could be reduced further. Another area where these biomarkers may prove useful is in active surveillance (AS) of men with low-risk prostate cancer. At present, none of the risk-stratification algorithms or routine parameters for AS incorporate F:T PSA. With increasing numbers of men choosing this management option, the validation of another tool for monitoring patients in this group -particularly one that is cheap and widely available -may be of significant value by reducing the burden of repeat imaging and prostate biopsies. One issue that may be of concern in the wider use of F:T PSA is the significant variation in test results determined by different testing methods. 15 Variation in the levels of standard PSA between laboratories is also an established concern, as well as inter-operator variation when estimating TRUS volume. This may compromise the reproducibility of PSAD. In this series all assays were performed at a single laboratory, minimising this potential problem, but caution must be taken when interpreting values taken from different laboratories.
Conclusion
The F:T PSA ratio with a cut-off value of 18% compares favourably with other currently available biomarkers for the diagnosis of clinically significant prostate cancer following transperineal template biopsies, and has the advantage of being widely available and relatively inexpensive. In this series both the PSAD and F:T PSA ratio performed better than PSA alone in the ability to predict clinically significant cancer. These results should serve to remind us of the potential usefulness of biomarkers that have perhaps previously been overlooked. We recommend the further evaluation of F:T ratio alongside imaging and PSAD for those men being considered for biopsy as well as those with low risk prostate cancer undergoing surveillance.
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